Company / Cost of Revenue
AYTU BIOPHARMA, INC Cost of Revenue History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$20.6M
FY2025
5-year range
$16.1M / $44.4M
FY2021-FY2025
Trend
+27.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue returned to growth in FY2025 after 2 years of decline, reaching $21M.
Based on SEC 10-K filings.
$21M in FY2025 with a 10-year CAGR of +72.5%.
Improved from $41M to $21M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -22.6%
- 5-Year CAGR
- +19.9%
- 10-Year CAGR
- +72.5%
Key checks
Key Insights
- 5-year CAGR of +19.9%, indicating consistent growth.
- In FY2025, cost of revenue increased 27.4% year-over-year.
- Peak cost of revenue was recorded in FY2022.
- Lowest cost of revenue in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.6M | +27.4% |
| FY2024 | $16.1M | -60.4% |
| FY2023 | $40.8M | -8.2% |
| FY2022 | $44.4M | +21.8% |
| FY2021 | $36.4M | +339.9% |
| FY2020 | $8.3M | +303.8% |
| FY2018 | $2.1M | +44.7% |
| FY2017 | $1.4M | +48.1% |
| FY2016 | $957.1K | +986.2% |
| FY2015 | $88.1K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026